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Dopamine replacement in the form of a levodopa/carbidopa
tablet has been the gold-standard therapy for Parkinson’s
disease (PD) for over six decades. Oral tablet dosing of LDOPA 3-4 times/day is quite efficacious in controlling earlystage PD symptoms). However, beyond its ~5-yr clinical
honeymoon period, this treatment becomes increasingly
associated with L-DOPA-induced dyskinesia (LID) and ‘ONOFF’ motor complications resulting from the non-continuous,
pulsatile delivery of L-DOPA to the brain. Addressing this
challenge, we devised an innovative strategy to supplement
the host’s microbiota with the human probiotic E.coli Nissle
1917 (EcN) genetically engineered to continuously produce LDOPA (EcNLDOPA) with no significant side effects. By
harnessing emerging synthetic biology and genetic
engineering technologies, we successfully established four
generations of EcNLDOPA(1-4) and characterized their ability to
endogenously synthesize L-DOPA from tyrosine using the
recombinant hpaB/C gene. The initially designed plasmidbased EcNLDOPA1,2 systems were further improved by
developing the chromosome-integrated and regulatable
systems EcN3-4L-DOPA using advanced Sce-ROPE genetic
engineering. The steady-state levels of plasma and brain LDOPA, dopamine and its metabolites, as well as gut
colonization of EcNLDOPA, were assessed over time. Our
results show that all EcNLDOPA strains effectively generate LDOPA in a dose- and time-dependent manner in vitro,
indicating that the biotherapeutic dosage can be personalized
to each patient’s needs. Our mouse pharmacokinetic studies
revealed that steady-state levels of plasma L-DOPA and brain
dopamine can be achieved by oral administration of EcNLDOPA.
Importantly, our pharmacodynamic efficacy studies of the LDOPA response in the progressive neurodegenerative
MitoPark mouse model of PD showed improved performance
in motor, cognitive and mood-related tasks. Colonization
studies show that our EcNLDOPA biotherapeutic requires only
once or twice daily dosing. Our novel reengineered, selfreplicating EcNLDOPA biotherapeutics offers an entirely new LDOPA treatment paradigm capable of ensuring long-term
efficacy while minimizing side-effects.
(NIH R61NS112441).
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The plasma membrane calcium ATPase (PMCA) is a
neuronal calcium transporter that plays a critical role in
regulating intracellular calcium levels by pumping calcium out
of cells, against its 10,000-fold concentration gradient.
Previous studies from our laboratory have shown that PMCA
undergoes a progressive reduction in activity and protein
levels with increasing age and in neurodegenerative
disorders. We have further demonstrated the unique
sensitivity of PMCA to oxidative stress. Loss of PMCA causes
dysregulation of calcium homeostasis, creates calcium
toxicity, and induces cell death. A mechanism to prevent loss
of PMCA and/or boost its activity would serve as a therapeutic
intervention to protect neurons. Polyunsaturated fatty acids
(PUFAs) have been shown to play a key role in brain
development and maintenance of neuronal homeostasis.
PUFA’s exert their effects through modulating membrane
fluidity, promoting neurite outgrowth, and impacting key
membrane proteins. The main goal of my studies was to
determine the effect of docosahexaenoic acid (DHA, 22:6 n3), an omega 3 fatty acid) on the neuronal PMCA. SHSY5Y
cells were differentiated by exposure to retinoic acid and
treated with DHA (10 µM-50 µM) for 24 hours. The cells were
assessed for viability by flow cytometry using propidium
iodide. PMCA activity was measured by monitoring Ca2+dependent ATP hydrolysis and PMCA protein levels were
determined by immunoblotting. Our results show that
exposure to DHA had no effect on cell viability (n=3). DHA
stimulated PMCA activity in a dose-dependent manner with a
3-4 fold increase observed at 50 µM DHA (n=5). DHA also
increased PMCA protein levels (n=4). Our results are the first
to demonstrate potential protection of PMCA by PUFAs such
as DHA. Ongoing studies are designed to investigate the
mechanisms underlying PMCA stimulation. Boosting PMCA
with PUFAs would preserve calcium homeostasis and protect
against neuronal cell death in aging and neurodegeneration.

doi: 10.1016/j.freeradbiomed.2021.12.252
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This state-of-the-art review provides an understanding of the
recent advances implicating tetrahydrobiopterin in cell death
mechanisms and possible novel therapeutic interventions.
Significance: Tetrahydrobiopterin is an essential cofactor for
five enzymes regulating cellular redox homeostasis, aromatic
amino acid metabolism, and neurotransmitter synthesis.
Deficiency in aromatic amino acid hydroxylases as well as the
tetrahydrobiopterin biosynthetic enzymes result in specific
clinical syndromes. However, the cell-specific factors
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